Turning Around One Of Biotech's Bellwethers: CEO Chris Viehbacher's Vision For Biogen episode artwork

EPISODE · Mar 10, 2025 · 10 MIN

Turning Around One Of Biotech's Bellwethers: CEO Chris Viehbacher's Vision For Biogen

from TD Cowen Insights · host TD Securities

Recorded on 03/03/25TD Cowen analyst Phil Nadeau speaks with Biogen CEO Chris Viehbacher from TD Cowen's 45th Annual Health Care Conference to discuss Mr. Viehbacher's strategy for turning around one of biotech's original bellwether companies. He describes his 5-year vision for Biogen, the path that he expects Biogen to take to return to revenue growth, and the role that business development will play in augmenting Biogen's pipeline and product portfolio. One of biotech's most experienced CEOs, Mr. Viehbacher shares his thoughts on the most striking ways that the biopharma industry has changed over the last decade, and the most important ways in which it has not. His insights are notable for anyone interested in Biogen, the biotech industry, or managing through challenge and change. https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Mar 10, 2025

Embed this episode

NOW PLAYING

Turning Around One Of Biotech's Bellwethers: CEO Chris Viehbacher's Vision For Biogen

0:00 10:50

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TD Cowen Insights?

This episode is 10 minutes long.

When was this TD Cowen Insights episode published?

This episode was published on March 10, 2025.

Can I download this TD Cowen Insights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!